WOLVERINE STACK

Description

This is a blend (10mg) each of BPC-157 (5mg) and TB-500 (5mg).

BPC-157 (short for Body Protection Compound-157) is a synthetic peptide derived from a protective protein found in gastric juice. First isolated in the 1990s, this partial sequence of body protection compound consists of 15 amino acids arranged in a specific sequence that appears to contribute to its biological activity. Its structure enables stability in gastric acid, unlike many other peptides that degrade in acidic environments. This unique property may contribute to its diverse effects across multiple tissue types.

TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4 (Tβ4), which is found in nearly all mammalian cells. The synthetic TB-500 represents the active segment of Tβ4, focusing on a specific portion believed to drive its biological activity.

While both peptides have been studied for tissue-regenerative properties, they appear to function through different mechanisms:

BPC-157 may work primarily through growth factor-mediated pathways and nitric oxide systems.
TB-500 appears to function mainly through actin-binding and subsequent cellular organization.

This mechanistic difference suggests they may have complementary effects when studied in laboratory settings, potentially affecting different aspects of the tissue repair process.

Properties of BPC-157

Peptide Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Chemical Formula: C62H98N16O22
Molecular Mass: 1419.5 g/mol
CAS Number: 137525-51-0
PubChem: 56843331

Properties of TB-500

Peptide Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ)
Chemical Formula: C38H68N12O14
Molecular Mass: 889.0 g/mol
CAS Number: 885340-08-9
PubChem: 62707662

Lyophilized Peptides

These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage. We do not use any fillers in this process.

This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use in humans. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides.

The potential synergistic effects of TB-500 and BPC-157 can be theorized based on their overlapping mechanisms in tissue repair, angiogenesis, and anti-inflammatory responses, as suggested by individual preclinical studies.

TB-500 primarily promotes cell migration, angiogenesis, and tissue regeneration by upregulating actin dynamics and modulating inflammation¹. BPC-157, for its part, enhances wound healing, angiogenesis, and tissue repair through its effects on nitric oxide pathways, vascular endothelial growth factor (VEGF), and anti-inflammatory mechanisms².

Both peptides share overlapping potential in promoting angiogenesis and reducing inflammation, which could amplify healing processes when combined. TB-500’s ability to stimulate endothelial cell migration may complement BPC-157’s role in stabilizing blood vessels and promoting microvascular growth. Their combined anti-inflammatory actions may also create a more favorable environment for tissue repair.

Although direct studies on their combined use are limited, their individual mechanisms suggest a strong theoretical basis for synergistic effects in tissue regeneration and recovery.

References

Su, L., Kong, X., Loo, S., Gao, Y., Liu, B., Su, X., Dalan, R., Ma, J., & Ye, L. (2022). Thymosin beta-4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells. Stem cell research & therapy, 13(1), 13. https://doi.org/10.1186/s13287-021-02687-x.
Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L. B., Pavlov, K. H., Petrovic, A., Sikiric, S., Vranes, H., Prtoric, A., Zizek, H., Durasin, T., Dobric, I., Staresinic, M., Strbe, S., Knezevic, M., Sola, M., Kokot, A., Sever, M., … Sikiric, P. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533.